Mutation of the TP53 gene at chromosome band 17p13 is the single most common genetic alteration found in human cancer, although the prevalence of TP53 mutations is considerably lower in hematological malignancies (o20%) compared with solid tumors (450%). 1 Nevertheless, TP53 mutations have been reported to be associated with poor prognosis in hematological malignancies, such as diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). 1 Furthermore, the profile of TP53 mutations appears to vary between different cancers, and a relationship has been found between certain carcinogens and specific mutation types. 2 Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma characterized by the t(11;14)(q13;q32), leading to cyclin D1 overexpression. MCL displays a high degree of genomic instability, reflected by a large number of secondary aberrations, and has an average survival of only 4-5 years. 3 However, the TP53 gene, which is an essential gene for genomic integrity, has not been extensively studied in MCL, although TP53 mutations have been reported more frequently in the clinically aggressive blastoid variant. 1 In one of the larger reports from the Leukemia and Lymphoma Molecular Profiling Project (LLMPP), TP53 mutations were found in 16/82 (20%) of MCL samples and were associated with an unfavorable clinical course. 4 That notwithstanding, the prognostic relevance of 17p deletions (which include the TP53 gene) in MCL is less clear, although several studies have indicated an association with short survival. 5 The aim of this study was to further investigate the mutation profile and prognostic impact of TP53 mutations and 17p deletion in a large cohort of 119 MCL patients collected at university hospitals in Sweden and Finland between 1983 and 2004 (median 1999). All cases fulfilled the World Health Organization diagnostic criteria for MCL, including overexpression of cyclin D1 and/or the presence of t(11;14)(q13;q32) as determined by immunostaining and fluorescence in situ hybridization, respectively. 6 Tumor samples were mainly obtained from lymph nodes, but also from spleen, tonsils, bone marrow or other tissues. The median age at diagnosis was 68 years (range, 45-97 years), the male:female ratio 3:1 and the median overall survival (OS) for the entire cohort was 36 months. Of the 118 cases with available histological data, 84 had classic MCL and 34 the blastoid variant. As expected, OS was significantly shorter among blastoid MCL cases than among classic MCL cases (median 24 vs 39 months, P ¼ 0.01, log rank test).
For the purpose of TP53 mutation detection, exons 4-8 of the TP53 gene were PCR amplified using genomic DNA and purified before sequencing as previously described. 7 These The 17p copy-number status at the TP53 locus was determined for all 119 MCL cases. A subset of cases had previously been investigated using either array-CGH (n ¼ 33) 8 or SNP arrays (n ¼ 29). 3 The 17p copy-number status was determined by real-time quantitative PCR (RQ-PCR) in the remaining 57 cases. The RQ-PCR was performed on genomic DNA using Maxima SYBR Green/ROX qPCR master mix (Fermentas, Burlington, ON, Canada), the Stratagene Mx 3005p (Stratagene, La Jolla, CA, USA) detection system and the Max Pro QPCR software (Stratagene). DNA copy number at 17p was normalized against two regions on chromosome 4 and copy-number ratios were calculated relative to a control DNA.
The prognostic impact of TP53 mutations and 17p deletions was investigated using the Kaplan-Meier method and differences in survival between patient groups were measured using the log-rank test. OS was measured from the date of diagnosis to either death or the last follow-up date (defined as censored).
Overall, 19 TP53 mutations were detected in 18/119 MCL cases, where one case carried a silent mutation and another case showed two TP53 mutations (Table 1) . Therefore, the prevalence of non-silent TP53 mutations was 14% (n ¼ 17) in the entire cohort, which is similar to or slightly lower than that reported by the LLMPP group (18-20%). 4, 9 There was no correlation between TP53 mutations and histology, as classic and blastoid MCL cases had similar mutation frequencies (13 vs 18%, P ¼ 0.6, Fisher's exact test). Although this seems to contrast with two older studies, both of these analyzed relatively few cases and included 'variant' cases with blastic, large-cell and anaplastic histology. 10, 11 As the pattern of TP53 mutations varies between different malignancies and may give clues to the underlying mutation mechanisms, we were interested in investigating the mutation spectrum in MCL, for example, molecular properties of mutations, presence of hotspot mutations and mutations in CpG dinucleotides (frequently mutated in cancers). 12 For the sake of comparison and to increase the number of mutations in the analysis, we combined our TP53 mutation data set (n ¼ 18) with previously identified TP53 mutations reported in MCL (n ¼ 55) and included in the IARC database (http://www-p53.iarc.fr/, version R15, November 2010). Overall, the mutation types and patterns were similar between the two cohorts ( Table 2) . Analysis of this combined data set of 73 TP53 mutations identified in MCL revealed that missense mutations were most frequent (77%), with nonsense mutations being the second most common type (11%). The majority of mutations were transitions (n ¼ 45, 62%), predominantly GC4AT transitions (n ¼ 40, 55%) at methylated CpG sites (n ¼ 23, 32%). This pattern is similar to what has been reported for 26 608 TP53 mutations in cancer in general in the IARC database, including DLBCL and CLL, although the latter had a lower prevalence of transitions at CpG sites (15%). 13 The exons most frequently targeted by mutations were exons 8 (n ¼ 26) and 5 (n ¼ 21), followed by exons 7 (n ¼ 13), 6 (n ¼ 8) and 4 (n ¼ 1) (Figure 1a ). The codons most frequently hit by mutations were at positions 176, 248 and 273 (Figure 1b) , which indicates that the classical mutation hot spots are also commonly affected in MCL. Hence, the analysis of the mutation profile in MCL did not reveal any striking diseasespecific features. Reported activity of p53 mutants according to the UMD p53 database. Numbers in parentheses represent the proportion of the remaining p53 transcriptional activity compared with wild-type p53 (100%). For three mutants a dominant-negative effect (DNE) has been confirmed. For two mutants the absence of a dominant-negative effect has been confirmed (*), whereas for the remaining mutants sufficient data on dominant-negative effect are lacking.
Letters to the Editor 17p deletions were considerably more frequent than TP53 mutations and were detected in 38/119 cases (32%). Although Bea et al.
14 reported a correlation between blastoid histology and 17p deletions, this observation was not confirmed in two subsequent studies 5, 15 nor in the present study, where an equal proportion of classic and blastoid MCL cases carried 17p deletion (31 vs 32%).
In all 9 cases (8%) carried both a TP53 mutation and a 17p loss. Therefore, 9 of 38 cases with 17p loss displayed TP53 mutations (24%), whereas 9 of 17 TP53 non-silent mutated cases had a concomitant 17p deletion (53%). These results are almost identical to those found in a recent study of MCL, where TP53 mutations were detected in 4/19 MCL cases with deletion of 17p (21%), and 17p deletions were also found in 4/7 MCL cases with TP53 mutations (57%). 9 Hence, in our cohort, 17p deletions were significantly more frequent in cases with TP53 mutations than in cases with no/silent mutations (9/17 vs 29/102, P ¼ 0.05, Fisher's exact test). In contrast, the majority of CLL cases with 17p deletion also carry a TP53 mutation (470%). 7, 16 In this cohort of MCL cases, which is the largest investigated so far, the presence of TP53 mutations was associated with a significant decrease in OS (P ¼ 0.006), as the median OS was only 13 months for TP53 mutated cases compared with 43 months for cases with a wild-type TP53 gene (Figure 2a ). This is in agreement with previous studies. 4, 9 Notably, the location of TP53 mutations has been shown to have prognostic implications in DLBCL, where mutations in the DNA-binding part were associated with poor survival, while mutations in portions of the non-DNA-binding domain had no impact on survival. 17 We did not identify such an association in our study of MCL (data not shown), probably because of the relatively small number of mutated cases available for analysis.
In contrast to TP53 mutations, the presence or absence of 17p deletions did not influence survival in our cohort (median OS, 39 months vs 35 months, respectively, P ¼ 0.7, Figure 2b) . Furthermore, the presence or absence of 17p deletion did not have any impact on survival within the group of TP53 mutated cases (OS, 9 vs 15 months, respectively, P ¼ 0.97, Figure 2c ). Less than half of the published studies (3 out of 7) analyzing the prognostic impact of genomic aberrations on MCL have found an association between 17p deletions and poor survival, whereas the remaining studies have not. 3, 14 Various techniques were used by these studies to estimate 17p copy number, such as metaphase CGH, array-CGH and SNP arrays. Importantly, however, our study is considerably larger than previous studies, some of which included as few as 30 patients compared with the 119 cases analyzed in the present study. This lack of prognostic power for 17p deletions in MCL contrasts sharply with CLL, where any type of mono-or biallelic TP53 disruption (del(17p) only, mutation only, or both mutation and del(17p)) predicts poor outcome. 1 A potential explanation for the difference between MCL and CLL in this regard may be the profound genetic instability, which is a major characteristic of MCL, but is lacking in CLL. Only a few of the large number of copy-number aberrations typically present in MCL have prognostic significance, the remainder being merely a consequence of genetic instability. 17p deletions may hence be 'overshadowed' by other chromosomal aberrations in MCL. In contrast, 17p deletions in CLL, although less frequent, are perhaps more likely to be significant and result from selective pressure.
Regardless, the different impact of TP53 mutations vs 17p deletions on survival in our MCL cohort is striking. Why would a loss of p53 function owing to a mutation in one of two alleles of the TP53 gene lead to poor clinical outcome but not a deletion of one TP53 allele? When a mutated form of the p53 protein forms tetramers with normal p53 protein molecules, the function of the entire tetramer may be compromised. 12 This dominantnegative effect may explain why p53, unlike other tumor suppressor genes, may not be deleted from cancer cell genomes but rather inactivated by missense mutations. In our cohort of TP53 mutations, five have been documented to exert a dominant-negative effect, whereas sufficient data are lacking Letters to the Editor on most other mutations (Table 1 ). In addition, certain TP53 mutations have been reported to demonstrate allele-specific 'gain-of-function', which confers new properties on the mutant p53 protein. The gained properties may include binding to other transcription factors (for example, p73), thus altering their function and causing increased cellular resistance to apoptosis and chemotherapy. 12 Hence, certain mutant p53 proteins may possess an oncogene activity and promote tumorigenesis.
Several missense mutations identified in our cohort have been reported to cause gain-of-function in yeast and human cell lines (data not shown), but additional studies are required.
In summary, we have analyzed the spectrum of TP53 mutations in MCL and confirmed the association of TP53 mutations with poor clinical outcome in the largest cohort of MCL patients studied so far. In contrast, the presence of 17p deletions did not appear to have any prognostic impact on MCL. However, owing to the retrospective nature of this analysis, future studies are needed to further investigate the implications of TP53 mutations and/or 17p deletions in MCL in the present era of advanced treatment strategies.
Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia The pathogenesis of chronic lymphocytic leukemia (CLL) remains incompletely understood. 1 Although acquired chromosomal aberrations have been demonstrated to influence CLL biology and clinical behavior, it remains unclear what single gene defects other than p53 or ATM mutations cause or contribute to the CLL phenotype. 2 In particular, recurrent gene mutations that are increasingly found in other hematological malignancies have not yet been identified in CLL. One recent CLL gene re-sequencing study reported the analysis of selected exons of 70 tyrosine kinase genes in 95 CLL patients and reported no somatically acquired mutations. 3 Given the frequent identification of stereotypical immunoglobulin receptor genes in CLL, it has been suggested that antigen engagement of the B-cell receptor on CLL cells serves a critical role in CLL cell survival and CLL disease etiology. Further, the reduced expression of del(13q)(14)-resident microRNAs has been implicated in early CLL pathogenesis in a subset of cases. 4 It is unknown whether CLL is driven by high-frequency recurrent gene mutations in one or a few genes.
To address this question for phosphokinases, we sequenced the coding regions of 515 kinases (for a listing of kinase genes sequenced and kinase family classification see Supplementary  Table S1 ) in DNA from CD19 þ sorted cells from 23 CLL cases. 5 This research was approved by the University of Michigan Institutional Review Board (IRBMED #2004-0962), and written informed consent was obtained from all patients before enrollment. CD19 þ and CD3 þ cells were purified from CLL samples using FACS as described. 6 Clinical and molecular characteristics of the CLL cases studied are summarized in Supplementary Table S2 . Primers used for sequence analysis of 8308 distinct coding exons from 515 kinase genes were derived from prior sequencing projects. 7 A summary of kinase gene reference sequences, primer sequences and exon coverage can be found in Supplementary Table S3 . Amplicons were sequenced unidirectionally. All mutations were confirmed in independently generated amplicons. A total of 9003 amplicons were considered to be of high enough quality to be scored for mutations. To be considered eligible for scoring at least 50% of the bases in 50% of the samples for a given amplicon had to have a Phred score of 20 and it further had to be judged to be of good quality by visual inspection. A total of 8798 (97.7%) amplicons of the 9003 reported in this study had 20 or more samples that were scored for mutations. Mutations were scored in all 24 samples for 6763 (75%) of the amplicons, and only 12 amplicons had as few as 12 samples that were scored. The average Phred score for all of the bases in all of samples in all of amplicons reported in this study was 54.3.
Six somatically acquired mutations were identified, each occurring once in the kinases WEE1, NEK1, BRAF, KDR, MAP4K3 and TRPM6 (Table 1) . Because clinically approved therapeutics that target BRAF are available, we subsequently analyzed all BRAF coding exons in 120 CLL cases and exons 11 and 15 selectively in an additional 130 cases (the sites for the vast majority of BRAF mutations affect amino acid residue 600 8 ). Primers to amplify and sequence all coding exons of BRAF and adjacent intronic sequences, including splice junctions, were designed using the primer 3 program (http://frodo.wi.mit. edu/primer3/) and sequence information was generated as described. 6 Somatic mutations were confirmed using paired patient CD3 þ /buccal DNA as templates. In total, four BRAF mutations were found, none involving BRAF amino acid residue 600 (Table 1 and Supplementary Table 2) .
Amino acid substitutions in WEE1, NEK1, BRAF, KDR, MAP4K3 and TRPM6 were also analyzed using the CHASM algorithm 9, 10 to estimate the probability that they impact protein activity in a manner relevant to oncogenicity. We trained an ensemble of decision trees 11, 12 (Random Forest) with 3285 likely oncogenic somatic missense mutations from the COSMIC database 13 and 3300 'passenger' mutations synthetically generated by a computer algorithm to mimic the cancer mutation spectrum. To ensure an unbiased score, 13 unique BRAF amino
